EULAR 2026: Immutep's IMP761 Phase I Data Preview

Key Takeaways

• Immutep is set to present Phase I data on IMP761 at the upcoming EULAR 2026 Congress.
• IMP761 represents a novel approach as a first-in-class LAG-3 agonist antibody targeting autoimmune diseases.
• Early Phase I data indicates a favorable safety profile for IMP761 in healthy participants.
• The clinical trial for IMP761 is progressing to the multiple ascending dose (MAD) phase.

Immutep SA will present Phase I clinical trial data for its investigational drug IMP761 at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, to be held in London from June 3–6, 2026. IMP761, a first-in-class LAG-3 agonist antibody, is being developed for the treatment of autoimmune diseases.

The EULAR Congress is a significant annual event focusing on rheumatology and autoimmune/inflammatory diseases. It provides a platform for researchers and clinicians to share the latest advancements in treatment and management strategies. Immutep's presentation of the IMP761 Phase I data adds to the anticipation surrounding novel therapeutic approaches in this field.

Immutep's IMP761 Phase I Data at EULAR 2026

Immutep's presentation will detail results from its placebo-controlled, double-blind, first-in-human Phase I study of IMP761. The single ascending dose (SAD) portion of the trial has been completed, with participants receiving doses up to 14 mg/kg. No significant safety concerns were observed during this phase. The trial is now advancing to the multiple ascending dose (MAD) phase to further evaluate the pharmacokinetics and safety profile of IMP761. Completion of the MAD phase is expected in Q3 2026.

About IMP761

IMP761 is a first-in-class LAG-3 agonist antibody designed to treat autoimmune diseases. As a LAG-3 agonist, IMP761 aims to modulate the immune system, reducing inflammation and mitigating disease activity. This novel approach holds promise for patients with autoimmune conditions where current treatments may be insufficient.

EULAR 2026 Congress Details

• Dates: June 3–6, 2026
• Location: London
• Focus: Rheumatology and autoimmune/inflammatory diseases

The EULAR 2026 Congress is a major venue for presenting clinical trial results and emerging therapeutic data in rheumatology. While specific details on other immunology drugs presented at EULAR 2026 are not yet available, the congress will likely feature discussions on a range of treatments for rheumatic and musculoskeletal diseases.

Market & Investor Implications

Immutep's presentation at EULAR 2026 could generate interest from investors and pharmaceutical companies focused on autoimmune disease therapies. Positive Phase I data for IMP761 could strengthen Immutep's position in the competitive landscape of immunology drug development.

What to Watch Next

The next key milestone for IMP761 will be the completion of the multiple ascending dose (MAD) phase, expected in Q3 2026. Data from the MAD phase will provide further insights into the safety, pharmacokinetics, and potential efficacy of IMP761. Future clinical trials will be needed to assess the drug's effectiveness in specific autoimmune diseases.

Frequently Asked Questions

• What is IMP761?

  IMP761 is a first-in-class LAG-3 agonist antibody being developed by Immutep for the treatment of autoimmune diseases.

• What is the significance of EULAR 2026?

  EULAR 2026 is the annual congress of the European Alliance of Associations for Rheumatology, a major event for sharing the latest advancements in rheumatology and autoimmune/inflammatory diseases.

• What data will Immutep present at EULAR 2026?

  Immutep will present Phase I data from its first-in-human study of IMP761, including safety and pharmacokinetic data.

• What is a LAG-3 agonist?

  A LAG-3 agonist is a type of immunotherapy that stimulates the LAG-3 protein, which can modulate the immune system and potentially reduce inflammation in autoimmune diseases.

• When is the MAD phase of the IMP761 trial expected to be completed?

  The multiple ascending dose (MAD) phase of the IMP761 trial is expected to be completed in Q3 2026.

References

1. Immutep Quarterly Activities Report Q3 FY26